SMOFLIPID 200mg ML
Active OLIVE / OIL FISH IN ACID OMEGA Spice 3/OLIO soybean / medium chain triglycerides
Group therapeutic intravenous solutions
Product Type DRUG RMS MAKES NO SSN scheme
Class C Type Recipe RNRL
Form Farm. INJECTIONS container BOTTLE
Commerc Data valid for 24 months. 26/05/2008
ATC B05BA02
Producer Price FRESENIUS KABI ITALY Srl
NAME
SMOFLIPID 200 MG / ML
Pharmacotherapeutic
Solutions for parenteral nutrition, lipid emulsions.
ACTIVE
1000 ml emulsion for infusion contains: soybean oil can
esterified 60.0 g; triglycerides Medium-chain 60.0 g, while olive oil
ified 50.0 g fish oil enriched in omega-3 acids 30.0 g, energy
already total 8.4 MJ / l (= 2000 kcal / l), about 8 pH, osmolality '
about 380 mOsm / kg.
EXCIPIENTS
glycerol, egg lecithin, (+/-)- alpha-tocopherol, water for preparation
oni injections, sodium hydroxide for pH adjustment, sodium ole
ato. INDICATIONS
lipid, including essential fatty acids and omega -3
to adult patients as part of a system of parenteral nutrition
and when oral or enteral nutrition and 'impossible, insufficient or contraindicated
.
CONTRAINDICATIONS / EFF.SECONDAR
hypersensitivity 'to the proteins of fish, egg, soy or peanut
or any of the active substances or excipients. Grave iperl
ipidemia. Severe renal impairment. Serious disturbances of blood coagulation
it. Severe renal insufficiency without possibility 'of hemophilia
traction or dialysis. Acute shock. General contraindications to therapy
ia infusion: acute pulmonary edema, and congestive overhydration
decompensated heart failure. Unstable conditions (eg severe post-traumatic condition
ni, decompensated diabetes mellitus, acute myocardial me
ocardio, stroke, embolism, metabolic acidosis, severe sepsis and dehydration
one hypotonic).
DOSAGE The dose and rate 'infusion are determined by their able
ta' of the patient to eliminate fat infusions. Adults: The dose standardized
de '1.0-2.0 g lipid / kg / day, equivalent to 5-10 ml / kg / day. L
to speed 'and recommended infusion' of 0.125 g lipid / kg / h, c
orrispondente SMOFlipid to 0.63 ml / kg / hour should not exceed 0,
15 g lipid / kg / hours, corresponding to 0.75 ml SMOFlipid / kg / hour. P
those companies pediatric Today there 'experience of drug use in pediatric patients
. Its use in pediatric patients and 'r
therefore limited partnership. Administration:
intravenous infusion through a peripheral vein or central.
STORAGE Store at room temperature not exceeding 25 degrees C. Do not freeze. Co
nservazione If after mixing the drug are made of a
ggiunte, from a microbiological point of view, mixtures
must be used immediately. If mixtures are used immediatament
and storage times after opening and storage conditions before use
action are the responsibility '
user and would normally not be longer than 24 hours at 2-8 degrees C, unless
that the additions were not made aseptically with
subsidiaries and validated.
WARNINGS
The ability 'to eliminate fat varies from individual to individual and therefore
' must be monitored according to clinical practice.
This is usually done by controlling the levels of triglycerides
. The serum triglyceride levels during infusion of
eve not exceed 3 mmol / l. An overdose can 'lead to subsidy
raccarico lipid syndrome. To date there is no 'experience in a
chin is extended beyond 14 days. This product contains
soybean oil, fish oil and egg phospholipids, which in rare cases cause allergic reactions in some
sent different. Allergies crusades were observed between
ate seeds soybean and peanuts. Use with caution in
condi tions of altered lipid metabolism, which can 'occur in patients co
n renal failure, diabetes mellitus, pancreatitis, impaired function
breathes' impairment, hypothyroidism, and sepsis. The clinical data in patients with diabetes mellitus or renal failure
are limited. The somministrazi
one of only medium-chain fatty acids can 'cause metabolic acidosis
a. The risk is' largely eliminated by the simultaneous infusion of
he long chain fatty acids contained in SMOFlipid. A concomitant somminist
ration of carbohydrates will destroy 're
this risk further. It is recommended, therefore, a simultaneous infusion of carbohydrates
or a solution of amino acids containing carbohydrates.
must be regularly checked and laboratory tests generally associated with hiatuses
monitoring intravenous nutrition. These
not understand the level of blood glucose, the function tests'
liver, acid-base metabolism, water balance, the total count of
blood and electrolytes. Any signs or symptoms of reaction ANAF
ilattica (such as fever, chills, rash or dyspnoea) should re port
immediate discontinuation of the infusion. Elevated levels of lipid
the plasma may interfere with some laboratory blood tests
I, such that for hemoglobin. The addition of a SMOFlipid
other body substances or drugs should generally be avoided unless the co
mpatibilita 'is known.
INTERACTIONS
Heparin given in clinical doses causes a temporary increase of
the release of lipoprotein lipase in the circulation. This can 'cause at the beginning
increased plasma lipolysis followed by a tempor
ANEA decrease in the elimination of triglycerides. The
soybean seed oil contains a natural amount of vitamin K 1. In SMOFlipid
content and 'so anyway' lower than expected un'influen
za significant effect on blood coagulation in patients treated with coumarin der
ivata.
SIDE EFFECTS
side effects observed during administration of the lipid emulsion
. Vascular diseases. Rare (> 1 / 10000, <1/1000): ipotension
and hypertension. Respiratory, thoracic and mediastinal.
Ra re: dyspnea. Gastrintestinali disorders. Uncommon (> 1 / 1000 <1/100):
loss of appetite, nausea, vomiting.
reproductive disorders TiVo and breast cancer. Very rare (<1/10000): priapismo. Patologie sis
Temic and conditions relating to the administration site. Common (>
1 / 100, <1/10): lieve aumento della temperatura corporea; poco comuni:
chills rare: hypersensitivity reactions' (ie anafilattich
eo anaphylactoid reactions, rash, urticaria, flushing heat cef
alea), feeling hot or cold, pallor, cyanosis, pain in neck, back
, bone, chest and back pain. If these side effects appear or if
during infusion
increase the level of triglycerides in the above 3 mmol / l, the infusion should be discontinued or, if you need
I continued at a reduced dose. The medicine should always be part
treatment of complete parenteral nutrition including
inoacidi am and glucose. Nausea, vomiting, and hyperglycemia have symptoms related to conditions that indicate
ati parenteral nutrition and may also be associated with this
parenteral nutrition. E '
recommended that monitoring of triglycerides, and blood glucose pe r
avoid high values \u200b\u200bthat could be harmful. S Syndrome
ovraccarico lipid impaired capacity 'to eliminate triglycerides
can' lead to "Fat overload syndrome" that can 'be
caused by overdose. Possible signs of metabolic overload
must be kept under observation. The cause can 'be genetic
(different metabolism from individual to individual), or lipid metabolism
can' be influenced by current or past illnesses. Que
's syndrome can 'arise ALSO' during a severe ipertriglicerid
emia, even at the speed 'recommended infusion and coinciding with a sudden change of
patient's clinical condition, as
impairment 'or kidney infection.
syndrome and fat overload and 'characterized by hyperlipemia, fever,
nfiltrazione fat, with or without jaundice, hepatomegaly, splenomegaly, a
Nemia, leukopenia, thrombocytopenia, coagulation disorders, haemolysis and reticulocytosis
, abnormal function tests' hepatic coma.
The symptoms are usually reversible if the infusion is stopped IPID
the emulsion. If signs of overload syndrome
co lipid infusion should be discontinued.
PREGNANCY AND LACTATION
There are no data on administration gr
greedy women during lactation. There are no studies on toxicity '
reproductive animals. Parenteral nutrition can 'become
necessary during pregnancy or breastfeeding. Give it to Don
pregnant and lactating women only after careful assess
tion.
0 comments:
Post a Comment